Straits Times Index
3,292.69 +10.64 (+0.32%) S&P 500
5,101.28 -14.89 (-0.29%) Dow
38,198.66 -187.43 (-0.49%) Nasdaq
15,930.03 -53.06 (-0.33%) Bitcoin USD
62,955.66 -677.18 (-1.06%) CMC Crypto 200
1,297.99 -41.07 (-3.07%)
Novartis AG (NOVN.SW)
| Previous close | 88.87 |
| Open | 88.86 |
| Bid | 89.39 x 0 |
| Ask | 89.40 x 0 |
| Day's range | 88.63 - 89.47 |
| 52-week range | 79.21 - 94.52 |
| Volume | |
| Avg. volume | 3,357,497 |
| Market cap | 182.413B |
| Beta (5Y monthly) | 0.47 |
| PE ratio (TTM) | 22.18 |
| EPS (TTM) | 4.03 |
| Earnings date | 18 Jul 2024 |
| Forward dividend & yield | 3.30 (3.71%) |
| Ex-dividend date | 07 Mar 2024 |
| 1y target est | 86.92 |
ZacksWhy This 1 Value Stock Could Be a Great Addition to Your Portfolio
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
ReutersMorphosys says takeover by Novartis on course after report of drug safety concern
BERLIN (Reuters) -Morphosys said its takeover by Novartis is still expected to close in the first half of this year, after a news report on a possible drug safety risk knocked the German biotechnology company's stock price on Monday. Morphosys' statement came after a report by specialist website STAT News, citing two people familiar with the matter, of a safety issue with its experimental drug pelabresib, which is being developed to treat myelofibrosis, a rare type of blood cancer affecting the bone marrow.
ZacksPharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
Merck (MRK), Sanofi (SNY), Novartis (NVS) and AstraZeneca (AZN) announce their first-quarter results.
